How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,615 results for

HIV Exposure

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Lopinavir/ritonavir (Kaletra) - human immunodeficiency virus (HIV-1) infected children aged from 14 days to less than 2 years old.

Lopinavir/ritonavir (Kaletra) - human immunodeficiency virus (HIV-1) infected children aged from 14 days to less than 2 years old. Lopinavir/ritonavir (Kaletra ® ). Reference number 3557 Page 1 of 3 Enc 7 Appx 2 AWMSG Secretariat Assessment Report – Limited submission Lopinavir/ritonavir (Kaletra ® ) 80 mg/20 mg oral solution Company: AbbVie Ltd. Licensed indication under consideration: In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (...) antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to less than 2 years old. Lopinavir/ritonavir oral solution is already licensed for use in patients aged 2 years and over in the same indication and is included on Welsh health board formularies. Marketing authorisation for this older age group was granted before 1 October 2010, and was not appraised by the All Wales Medicines Strategy Group (AWMSG) as it did not meet the criteria

2018 All Wales Medicines Strategy Group

2. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza) - Human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza) - Human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza ® ). Reference number 2418. Page 1 of 3 Enc 9 Appx 2 AWMSG Secretariat Assessment Report – Limited submission Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza ®? ) 800 mg/150 mg/200 mg/10 mg film-coated tablet Company: Janssen-Cilag Ltd Licensed indication under (...) consideration: Treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg). ? This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Marketing authorisation date: 26 September 2017 Comparator(s) ? Darunavir/cobicistat (Rezolsta ® ) in combination with emtricitabine

2018 All Wales Medicines Strategy Group

3. Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) adults infected with human immunodeficiency virus-1 (HIV-1)

Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) adults infected with human immunodeficiency virus-1 (HIV-1) AWMSG SECRETARIAT ASSESSMENT REPORT Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy ® ) 50 mg/200 mg/25 mg film-coated tablets Reference number: 3414 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics & Toxicology Centre (AWTTC). Please direct any queries to AWTTC: All Wales Therapeutics & Toxicology Centre (AWTTC) University Hospital (...) from the date of the Final Appraisal Recommendation. AWMSG Secretariat Assessment Report Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy ® ? ) 50 mg/200 mg/25 mg film-coated tablets 1.0 KEY FACTS Assessment details Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy ® ? ) for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. ?This medicinal

2018 All Wales Medicines Strategy Group

4. Dolutegravir rilpivirine (Juluca) - For the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA copies <50 copies/mL) on a stable antiretroviral regimen

Dolutegravir rilpivirine (Juluca) - For the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA copies <50 copies/mL) on a stable antiretroviral regimen Published 10 September 2018 1 dolutegravir 50mg / rilpivirine 25mg film-coated tablets (Juluca ® ) SMC2091 ViiV Healthcare Ltd. 10 August 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug (...) and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission dolutegravir / rilpivirine film-coated tablet (Juluca ® ) is accepted for use within NHSScotland. Indication under review: The treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA 50 copies/mL in the 6-month period before screening and no more than one instance of viral load >50 copies/mL but <200 copies/mL

2018 Scottish Medicines Consortium

5. Human Immunodeficiency Virus (HIV) Infection: Screening

Human Immunodeficiency Virus (HIV) Infection: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Pregnant persons The USPSTF recommends that clinicians screen for HIV infection in all pregnant persons, including those who present in labor or at delivery whose HIV status is unknown. A Adolescents and adults aged 15 to 65 years The USPSTF recommends that clinicians screen for HIV infection in adolescents (...) . In addition, ART treatment in pregnant persons living with HIV and use of other precautions substantially decrease the risk of transmission to the fetus, newborn, or infant. Abbreviations: ACOG=American College of Obstetricians and Gynecologists; AIDS=acquired immunodeficiency syndrome; ART=antiretroviral therapy; CDC=Centers for Disease Prevention and Control; HIV= human immunodeficiency virus; STI=sexually transmitted infection. For a summary of the evidence systematically reviewed in making

2019 U.S. Preventive Services Task Force

6. Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis

Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Persons at high risk of HIV acquisition The USPSTF recommends that clinicians offer preexposure prophylaxis (PrEP) with effective antiretroviral therapy to persons who are at high risk of HIV acquisition. A View the Clinical Summary in Population Persons at high risk of HIV acquisition (...) Once-daily oral treatment with combined tenofovir disoproxil fumarate and emtricitabine is the only formulation of PrEP currently approved by the US Food and Drug Administration for use in the United States in persons at risk of sexual acquisition of HIV infection. Relevant USPSTF Recommendations The USPSTF has issued recommendations on behavioral counseling to reduce risk of STIs and on screening for HIV infection. Abbreviations: HIV=human immunodeficiency virus; STI=sexually transmitted infection

2019 U.S. Preventive Services Task Force

7. Prenatal and Perinatal Human Immunodeficiency Virus Testing - Expanded Recommendations

Prenatal and Perinatal Human Immunodeficiency Virus Testing - Expanded Recommendations Prenatal and Perinatal Human Immunodeficiency Virus Testing - Expanded Recommendations - ACOG Menu ▼ Prenatal and Perinatal Human Immunodeficiency Virus Testing - Expanded Recommendations Page Navigation ▼ INTERIM UPDATE Number 752 (Replaces Committee Opinion No. 635, June 2015) Committee on Obstetric Practice HIV Expert Work Group This Committee Opinion was developed by the American College of Obstetricians (...) advances in the prevention of perinatal transmission of human immunodeficiency virus (HIV), it is clear that early identification and treatment of all pregnant women with HIV is the best way to prevent neonatal infection and also improve women’s health. Furthermore, new evidence suggests that early initiation of antiretroviral therapy in the course of infection is beneficial for individuals infected with HIV and reduces the rate of sexual transmission to partners who are not infected. Screening should

2018 American College of Obstetricians and Gynecologists

8. Labor and Delivery Management of Women With Human Immunodeficiency Virus Infection

of pregnant women during pregnancy and delivery to prevent mother-to-child transmission of the human immunodeficiency virus (HIV). Prevention of transmission of HIV from the woman to her fetus or newborn is a major goal in the care of pregnant women infected with HIV. Continuing research into mother-to-child transmission of HIV has suggested that a substantial number of cases of perinatal HIV transmission occur as the result of fetal exposure to the virus during labor and delivery. The precise mechanisms (...) Labor and Delivery Management of Women With Human Immunodeficiency Virus Infection Labor and Delivery Management of Women With Human Immunodeficiency Virus Infection - ACOG Menu ▼ Labor and Delivery Management of Women With Human Immunodeficiency Virus Infection Page Navigation ▼ Number 751 (Replaces Committee Opinion No. 234, May 2000) Committee on Obstetric Practice HIV Expert Work Group The Society for Maternal–Fetal Medicine endorses this document. This Committee Opinion was developed

2018 American College of Obstetricians and Gynecologists

9. Emtricitabine/Tenofovir disoproxil Zentiva - human immunodeficiency virus type 1 (HIV-1)

Emtricitabine/Tenofovir disoproxil Zentiva - human immunodeficiency virus type 1 (HIV-1) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 15 September 2016 EMA/650230/2016 Committee for Medicinal Products for Human Use (CHMP (...) efavirenz Assessment report EMA/650230/2016 Page 4/28 eGFR estimated glomerular filtration rate EMA European Medicines Agency ESRD end-stage renal disease FDA U.S. Food and Drug Administration FTC emtricitabine GC gas chromatography GCP good clinical practise GFR glomerular filtration rate h hour HAART highly active antiretroviral therapy HBeAg hepatitis B e antigen HBV hepatitis B virus HDL high-density lipoprotein HDPE high density polyethylene HIV human immunodeficiency virus HPLC high performance

2016 European Medicines Agency - EPARs

10. HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis (PrEP)

HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis (PrEP) © 2014 Kaiser Foundation Health Plan of Washington. All rights reserved. 1 HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis (PrEP) Guideline Background 2 Screening Recommendations HIV Test Ordering and Consent 2 Indications for Periodic HIV Screening 3 Referrals 3 Follow-up and Monitoring 4 Pre-Exposure Prophylaxis (PrEP) 4 Evidence Summary 5 References 6 Guideline Development Process (...) contained in the guidelines may not be appropriate for use in all circumstances. The inclusion of a recommendation in a guideline does not imply coverage. A decision to adopt any particular recommendation must be made by the provider in light of the circumstances presented by the individual patient. 2 Background Of the approximately 1.2 million people living with HIV (human immunodeficiency virus) in the United States, 20–25% are unaware that they are infected. In Washington State, about 12,000 people

2013 Kaiser Permanente Clinical Guidelines

11. Understanding the magnitude of occupational exposure to human immunodeficiency virus (HIV) and uptake of HIV post-exposure prophylaxis among healthcare workers in a rural district in Tanzania. (Abstract)

Understanding the magnitude of occupational exposure to human immunodeficiency virus (HIV) and uptake of HIV post-exposure prophylaxis among healthcare workers in a rural district in Tanzania. Occupational exposure to blood or other body fluids in healthcare settings puts healthcare workers (HCWs) at risk of acquiring human immunodeficiency virus (HIV) infection. It is estimated that between 200 and 5000 HIV infections are transmitted annually to HCWs worldwide. Use of post-exposure prophylaxis (...) (PEP) has been documented to reduce the rate of HIV infection from workplace exposures by 81%.To investigate the extent of occupational exposure to HIV infection during the period of 12 months before the survey and to identify factors associated with uptake of PEP services among HCWs.We interviewed 221 HCWs from selected healthcare facilities in Kongwa, Tanzania. Data included occupational exposures to body fluids, knowledge and use of PEP.Sixty (27.1%) of the HCWs had experienced exposures

2017 Journal of Hospital Infection

12. Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients. Full Text available with Trip Pro

Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients. Combined antiretroviral therapy (cART) has improved survival in HIV-patients. While the first antiretrovirals, which became available in particular D-drugs (especially didanosine and stavudine) and unboosted protease inhibitors, may impair liver function, the modern cART seems to decrease liver fibrosis. This study assessed the influence of exposure (...) to previous antiretrovirals on liver fibrosis in HIV-infected patients.This observational cross-sectional single-center study recruited 333 HIV patients and assessed liver fibrosis using transient elastography (TE).83% were male with a median age of 45, while 131 were co-infected with viral hepatitis. Overall, 18% had significant fibrosis and 7.5% had cirrhosis. 11% of HIV mono-infected patients had significant fibrosis and 2% had cirrhosis. HCV infection (OR:5.3), history of exposure to didanosine

2018 PLoS ONE

13. Human Immunodeficiency Virus and Hepatitis B Virus Infection Prevention Following Occupational Exposure among Staff at a Regional Referral Hospital in Western Kenya Full Text available with Trip Pro

Human Immunodeficiency Virus and Hepatitis B Virus Infection Prevention Following Occupational Exposure among Staff at a Regional Referral Hospital in Western Kenya Postexposure prophylaxis (PEP) with antiretroviral therapy (ART) and vaccination against hepatitis B virus (HBV) aides in preventing human immunodeficiency virus (HIV) infection and HBV, respectively, from accidental or occupational exposure. We assessed compliance to guidelines for HIV and HBV prevention after occupational exposure (...) was considered statistically significant.Majority of documented hospital staff (n = 52) were health workers (63%) and students (27%) and had high HIV risk exposures (97%). All had timely PEP initiation with 50% completing PEP. Completion rates did not vary by gender (P = 0.78), exposure type (P = 1.0), or department of exposure (P = 0.75). Retesting for HIV and negativity rates at months 1.5, 3, and 6 were 96%, 25%, and 17% and 100%, 100%, and 100%, respectively. At the time of exposure, 17% (9) of staff

2018 International journal of preventive medicine

14. Prescribing of Human Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis by HIV Medical Providers in the United States, 2013–2014 Full Text available with Trip Pro

Prescribing of Human Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis by HIV Medical Providers in the United States, 2013–2014 Clinical trials have demonstrated the effectiveness of human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) for reducing HIV acquisition. Understanding how HIV care providers are prescribing PrEP is necessary to ensure success of this prevention strategy.During 2013-2014, we surveyed US HIV care providers who also provided care to HIV-negative (...) patients. We estimated percentages who had prescribed PrEP and assessed associations between provider characteristics and PrEP prescribing.An estimated 26% (95% confidence interval [CI], 20-31) had ever prescribed PrEP. Of these, 74% (95% CI, 61-87) prescribed for men who have sex with men (MSM), 30% (95% CI, 21-39) for women who have sex with men, 23% (95% CI, 9-37) for men who have sex with women, 23% (95% CI, 15-30) for uninfected partners in HIV-discordant couples trying to conceive, and 1% (95% CI

2017 Open forum infectious diseases

15. Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. (Abstract)

Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors.Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD (...) , the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r).The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio

2019 Journal of Infectious Diseases

16. Human immunodeficiency virus (HIV) among men who have sex with men: results of the first integrated biological and behavioral survey in Burkina Faso, West Africa. Full Text available with Trip Pro

Human immunodeficiency virus (HIV) among men who have sex with men: results of the first integrated biological and behavioral survey in Burkina Faso, West Africa. Many men who have sex with men (MSM) are at significant risk for HIV infection. The objective of this study was to determine the prevalence and correlates of HIV infection among MSM in Burkina Faso.A cross-sectional biological and behavioral survey was conducted from January to August 2013 among MSM in Ouagadougou and Bobo-Dioulasso (...) survey among MSM in Burkina Faso suggest a need for programs to raise awareness among MSM and promote safer sex, particularly for young MSM to prevent HIV transmission. These programs would need support from donors for innovative actions such as promoting and providing pre-exposure prophylaxis, condoms and water-based lubricants, HIV counseling, testing, early treatment initiation and effective involvement of the MSM communities.

2019 BMC Public Health

17. Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Pre-exposure Prophylaxis among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study. Full Text available with Trip Pro

Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Pre-exposure Prophylaxis among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study. Young men who have sex with men (MSM) are among the most vulnerable to HIV infection in the United States. While pre-exposure prophylaxis (PrEP) has demonstrated effectiveness, adherence and retention in care have been low among youth.We conducted a randomized controlled trial to evaluate (...) the impact of a youth-tailored, bi-directional text-messaging PrEP support intervention (PrEPmate) on study retention and PrEP adherence. Young individuals at risk for HIV acquisition initiating PrEP within Chicago's safety-net hospital system were randomized 2:1 to receive PrEPmate or standard of care (SoC) for 36 weeks. The primary retention outcome was study-visit completion, and the primary adherence outcome was tenofovir diphosphate (TFV-DP) concentrations ≥700 fmol/punch (consistent with ≥4 doses

2018 Clinical Infectious Diseases Controlled trial quality: predicted high

18. In Vitro Exposure to Prostratin but Not Bryostatin-1 Improves Natural Killer Cell Functions Including Killing of CD4+ T Cells Harboring Reactivated Human Immunodeficiency Virus Full Text available with Trip Pro

In Vitro Exposure to Prostratin but Not Bryostatin-1 Improves Natural Killer Cell Functions Including Killing of CD4+ T Cells Harboring Reactivated Human Immunodeficiency Virus In the attempt of purging the HIV-1 reservoir through the "shock-and-kill" strategy, it is important to select latency-reversing agents (LRAs) devoid of deleterious effects on the antiviral function of immune effector cells. Here, we investigated two LRAs with PKC agonist activity, prostratin (PRO) and bryostatin-1 (BRY (...) ), for their impact on the function of natural killer (NK) cells, the major effectors of innate immunity whose potential in HIV-1 eradication has emerged in recent clinical trials. Using NK cells of healthy donors, we found that exposure to either PRO or BRY potently activated NK cells, resulting in upmodulation of NKG2D and NKp44 activating receptors and matrix metalloprotease-mediated shedding of CD16 receptor. Despite PRO and BRY affected NK cell phenotype in the same manner, their impact on NK cell function

2018 Frontiers in immunology

19. Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents

Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You (...) have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before

2018 Clinical Trials

20. Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women

Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03564613 Recruitment

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>